Tezacaftor (VX-661) + Ivacaftor Launch Insights 2018 with Sales Forecasts to 2022 - ResearchAndMarkets.com

DUBLIN--()--The "Tezacaftor (VX-661) + Ivacaftor - Launch Insight, 2018" report has been added to ResearchAndMarkets.com's offering.

The report covers all the indications for which the Tezacaftor (VX-661) + Ivacaftor is being developed and also provides the competitive landscape for the major indications. The report further includes patent details and forecasted sales till 2022.

The report will provide a clear picture of market positioning of the upcoming launch of Tezacaftor (VX-661) + Ivacaftor and will also provide the insight about how Tezacaftor (VX-661) + Ivacaftor will evolve in the market as well as within its respective class. Report provides detailed information of clinical trials that have been or are being conducted for this product. Analysis and Insightful information around the clinical trials is provided by assessment of the trial results.

Key Features:

  • In-depth analysis and insightful information around the clinical trials provided by assessment of the trial results. Assisting understanding of how upcoming launches can be blockbuster in their respective classes
  • Attribute analysis has been done by scrutinizing data from all key clinical trials for the products that will enhance assessment of drugs through competitive scoring in relation to other competitors (both marketed and pipeline)
  • A thorough head to head comparison with marketed products (if available) is carried out
  • Product class share evolution has been provided till 2022, providing a thorough assessment of how the launch of these products will affect the current and future market trends
  • Competitive Landscape Profile of the products assist in identifying potential competitors

Key Topics Covered:

Report Introduction

Tezacaftor (VX-661) + Ivacaftor Overview

Tezacaftor (VX-661) + Ivacaftor of action

Pre-clinical Characterization

  • Indication 1
  • Indication 2

Clinical Characterization

  • Indication 1
  • Indication 2

Product Developmental Activities

  • Collaboration
  • Mergers & Acquisitions
  • Financing

Tezacaftor (VX-661) + Ivacaftor Market Evolution

Tezacaftor (VX-661) + Ivacaftor Class Share Evolution

Tezacaftor (VX-661) + Ivacaftor Market Positioning

Patent Expiry Analysis

Competitive Landscape for the Tezacaftor (VX-661) + Ivacaftor in major indications

For more information about this report visit https://www.researchandmarkets.com/research/lxqtbp/tezacaftor?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs